Details
Category: Volume 08 Issue 07 July 2020
Hits: 1082

Title: Clinical Presentation of Sarcoidosis in El-Minia Governorate (Egyptian Local Experience)

Authors: Nezar Refat, Bahaa Ibrahim Mohamed, Ahmed Rawy Abo-elyazed

 DOI: https://dx.doi.org/10.18535/jmscr/v8i7.30

Abstract

Background: The exact course of sarcoidosis is still unknown, ranging from spontaneous remission with no treatment in 2/3 of cases and in the remaining 1/3 of the cases long-term treatment is needed. Chest computed tomography (CT); is beneficial to judge potentially reversible from irreversible (fibrotic) lung damages.

Patients and Methods: This work was a retrospective study included 30 patients with sarcoidosis who were presented as out-patients to chest clinic from 2012 to 2017.

Results: This study included 30 patients; 8 males and 22 females. Their age ranged from 32-62 years with mean and SD 45.1 ±10.49. Dyspnea grade 2 and 3 was the commonest symptom present in 28 patients, followed by cough in 24 patients. Ocular manifestations were also common, chest pain and CNS manifestation were found in 4 patients. Bilateral hilar lymph node enlargements (BHLs) were suspected in 25 patients at x ray film and detected in 24 patients on MDCT study. Also, on MDCT, nodular shadows were seen in 16 patients and ground glass opacities identified on 11 patients.17 cases were diagnosed by biopsy, Heerford syndrome in 2 cases and Lofgreen syndrome in 4 cases and 7 patients refused biopsy but had typical radiological and clinical scenario of sarcoidosis.

Conclusion: Diagnosis of sarcoidosis can be made by highly specific clinical and radiological manifestations with exclusion of other differential diagnosis, mainly TB and lymphoma. Radiological findings were more specific regarding their distribution that mostly preferred the middle and lower lung zones.

References

  1. Iannuzzi MC and Fontana JR.: Sarcoidosis: Clinical presentation, immunopathogenesis and therapeutics. JAMA.,2011; 305(4):391-9.
  2. Hunninghake GW, Costabel U, Ando M, et al: ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/ European Respiratory Society/World Association of Sarcoidosisand other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis.,1999;16:149 -73.
  3. Navani N, Lawrence DR, Kolvekar S, et al.: Endobronchial ultrasound-guided transbronchial needle aspiration prevents mediastinoscopies in the diagnosis of isolated mediastinal lymphadenopathy: a prospective trial. Am J Respir Crit Care Med.,2012;186(3):255–60.
  4. Baughman RP, Nunes H, Sweiss NJ, et al: Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J.,2013; 41(6):1424–38.
  5. Sweiss NJ, Barnathan ES, Lo K, et al.: C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis.,2010;27(1):49-56.
  6. Baughman RP, Nagai S, Balter M, et al.: Defining the clinical outcomestatus (COS) in sarcoidosis: results of WASOG task force. Sarcoidosis Vasc Diffuse Lung Dis.,2011;28(1):56-64.
  7. Mukhopadhyay S, Wilcox BE, Myers JL, et al: Pulmonary necrotizing granulomas of unknown cause: clinical and pathologic analysis of 131 patients with completely resected nodules. Chest, 2013;144:813-24.
  8. Valeyre D, Bernaudin J-F, Florence J, et al.: Pulmonary sarcoidosis. Clin Chest Med., 2015;36(4):631-41.
  9. Robert P. Baughman, Ronald G. Crystal, Daniel A. Culver et al: Sarcoidosis in America. Analysis Based on Health Care Use Annals ATS., 2016; Volume 13 Number 8August.
  10. Elizabeth V. Arkema, Johan Grunewald, Susanna Kullberg, et al: Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden European Respiratory Journal; DOI: 10.1183/13993003.00477-2016.
  11. Bresnitz EA and Strom BL: Epidemiology of sarcoidosis. Epidemiol Rev., 1983; 5: 124–156.
  12. An-Ten Berge B, Paats MS, Bergen IM, et al. Increased IL‑17A expression in granulomas and in circulating memory T-cells in sarcoidosis. Rheumatology (Oxford) 2012; 51: 37‑
  13. Bn-Douglas JG, Middleton WG, Gaddie J, et al. Sarcoidosis: A disorder commoner in non‑smokers? Thorax,1986; 41: 787‑
  14. Cn- Valeyre D, Soler P, Clerici C, et al. Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. Thorax, 1988; 43: 516‑
  15. Urbankowski T, Knyziak-Medrzycka I, Domagała-Kulawik J, et al:[Sarcoidosis and tobacco smoking--clinical picture, diagnostic tests results and bronchoalveolar lavage fluid composition]. 2012; 32(191):298-301.
  16. Dn- Domagala‑Kulawik J (2008). Effects of cigarette smoke on the lung and systemic immunity. J Physiol Pharmacol., 2008;59:19‑
  17. Jill F. Zeitlin, Thomas A. Tami and Robert Baughman:First Published May 1. 2000, Volume: 14 issue: 3, page(s): 157-162. Departments of Otolaryngology, Cincinnati, Ohio Departments of Pulmonology, University of Cincinnati, Cincinnati, Ohio.
  18. Heinrich J, Richter K, Frye C, et al. [European Community Respiratory Health Survey in Adults (ECRHS)].Pneumologie, 2002;56 (5):297-303.
  19. Renato Vianna Soares, Anne Forsythe, Kyle Hogarth, et al: Gastroenterol, 2011; Vol.48 no.2 São Paulo Apr./June Respir Crit Care Med. 163(2):329–334.
  20. El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review., 2014;63:871-80.
  21. 21- De Boer S1, Kolbe J and Wilsher ML: The relationships among dyspnoea, health-related quality of life and psychological factors in sarcoidosis. Respirology, 2014; 19(7):1019-24.
  22. Kiter G, Müsellim B, Cetinkaya E, Türker H, et al: Clinical presentations and diagnostic work-up in sarcoidosis: a series of Turkish cases (clinics and diagnosis of sarcoidosis). TuberkToraks, 2011;59: 248-58.
  23. JL Wait and A Movahead1.Anginal chest pain in sarcoidosis.Thorax, 1989; 44(5): 391-95.
  24. Mihailovic-Vucinic V and Jovanovic D.: Pulmonary sar­coidosis. Clin Chest Med., 2008; 29(3): 459-73.
  25. Kalkanis A and Judson MA: Distinguishing asthma from sarcoidosis: an approach to a problem that is not always solvable. J Asthma, 2013;50(1):1-6.
  26. Tugal-Tutkun I: Systemic vasculitis and the eye. Curr Opin Rheumatol., 2017;29(1):24–32.
  27. Culver DA, Dahan A, Bajorunas D, et al.: Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis- Associated small nerve fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci.,2017; 58(6):52-60.
  28. Velter C and Lipsker D: Cutaneous panniculitis. Rev Med Intern., 2016; 37(11):743-50.
  29. Ebert EC, Kierson M and Hagspiel KD: Gastrointestinal and hepatic manifestations of sarcoidosis. Am J Gastroenterol.; 2008;103:3184-92.
  30. Elgharably A, Gomaa AI, Crossey MM, et al.Hepatitis C in Egypt – past, present, and future. Int J Gen Med., 2016; 20(10):1-6.
  31. Chapelon-Abric C, De Zuttere D, Duhaut P, et al.: Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore),2004; 83(6):315-34.
  32. Tatiana Kuznetsova, Lieven Herbots, Begoña López, et a. Prevalenceof Left Ventricular Diastolic Dysfunction in a General Population. Circulation: Heart Failure, 2009;2:105-12.
  33. Shorr AF, Davies DB and Nathan SD: Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest, 2003;124:922-8.
  34. Bourbonnais JM and Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis.Eur Respir J.,2008;32:296–302.
  35. Alhamad E, Cal J, Alfaleh H, et al. Pulmonary hypertension in Saudi Arabia: A single center experience.Ann Thorac Med., 2013;8:78.
  36. Gerke AK and Hunninghake G.: The immunology of sarcoidosis. Clin Chest Med., 2008;29(3):379-90.
  37. Berliner AR, Haas M and Choi MJ: Sarcoidosis: The nephrologist’s perspective. Am J Kidney Dis., 2006;48 (5):856-70.
  38. Rothkrantz-Kos S, Dieijen-Visser MP, Mulder PG, et al: Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem., 2003; 49:1510-17.
  39. Lynch JP III, Kazerooni EA and Gay SE: Pulmonary sarcoidosis. Clin Chest Med., 1997;18:755-85.
  40. Lynch JP III: Computed tomographic scanning in sarcoidosis. Semin Respir Crit Care Med., 2003;24:393–418.
  41. Semin Roentgenol Little B: Sarcoidosis: Overview of pulmonary manifes­tations and imaging, 2015; 50(1): 52-64.
  42. Criado E, Sanchez M, Ramirez J, et al.: Pulmonary Sarcoidosis: Typical and atypical manifestations at high-resolution CT with pathologic correlation. Radi­ographics, 2010; 30(6): 1567-86.
  43. Keijsers R, Veltkamp M, Grutters J: Chest imaging. Clin Chest Med., 2015; 36(4): 603-19.
  44. Huggins JT, Doelken P, Sahn SA, et al : Chest, 2006;129(6):1599-604.
  45. Müller NL, Kullnig P and Miller RR. : The CT findings of pulmonary sarcoidosis: analysis of 25 patients. AJR Am J Roentgenol, 1989;152:1179-82.
  46. Spagnolo P, Sverzellati N, Wells A, et al: Imaging as­pects of the diagnosis of sarcoidosis. Eur Radiol., 2014; 24(4):807-16.
  47. Calaras D, Munteanu O, Scaletchi V, et al: Ventilatory disturbances in patients with intrathoracic sarcoidosis – a study from a functional and histological perspective. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017;34:58-67.
  48. Baratto L, Park SY, Hatami N, et al: 18F-FDG silicon photomultiplier PET/CT: a pilot study comparing semi-quantitative measurements with standard PET/CT. PLoS One,2017;12(6):e0178936.
  49. Carter JM, Howe BM and Inwards CY: Conditions simulating primary bone neoplasms. Surg Pathol Clin., 2017;10(3):731-48.
  50. Gupta D, Chetty M, Kumar N, et al: Anergy to tuberculin in sarcoidosis is not influenced by high prevalence of tuberculin sensitivity in the population. Sarcoidosis Vasc Diffuse Lung Dis., 2003;20(1):40-45.
  51. Ahmadzai H, Cameron B, Chui JJ, et al: Peripheral blood responses to specific antigens and CD28 in sarcoidosis. Respir Med., 2012;106(5):701-09
  52. Judson MA, Chaudhry H, Louis A, et al.: The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med., 2015;109(4):526-31.
  53. Schutt AC, Bullington WM and Judson MA: Pharmacotherapy for pulmonary sarcoidosis. Respiratory Medicine, 2010; 104(5): 717-23.
  54. Cremers JP, Drent M, Bast A, et al.: Multinational evidence-based world association of sarcoidosis and other granulomatous disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. CurrOpinPulm Med., 2013; 19:545-61.

Corresponding Author

Bahaa Ibrahim Mohamed

Department of Chest Clinics, Minia University Hospital, El Minia, Faculty of Medicine, Egypt